Clinical benefit of subsequent chemotherapy after drug-induced interstitial lung disease in pancreatic cancer patients: a multicenter retrospective study from Japan

PURPOSE: Drug-induced interstitial lung disease (ILD) is not a rare adverse event in the current chemotherapy strategy for pancreatic ductal adenocarcinoma (PDAC). Thus, we aimed to find the optimal management for PDAC patients with a history of ILD induced by a gemcitabine-based regimen. METHODS: W...

Descripción completa

Detalles Bibliográficos
Autores principales: Irie, Hiroki, Suzuki, Rei, Okubo, Yoshinori, Asama, Hiroyuki, Konno, Naoki, Noguchi, Yuki, Watanabe, Ko, Shibukawa, Goro, Imamura, Hidemichi, Takagi, Tadayuki, Sugimoto, Mitsuru, Sato, Yuki, Nakamura, Jun, Kato, Tsunetaka, Hashimoto, Minami, Yanagita, Takumi, Hikichi, Takuto, Ohira, Hiromasa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10080831/
https://www.ncbi.nlm.nih.gov/pubmed/37024781
http://dx.doi.org/10.1186/s12885-023-10781-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10080831/
https://www.ncbi.nlm.nih.gov/pubmed/37024781
http://dx.doi.org/10.1186/s12885-023-10781-x

Ejemplares similares